« Back to Record
Citation APA

Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, D., Cobleigh, M., Di Leo, A., Johnston, S. R. D. S., Gasparini, G., Kaufman, B., Marty, M., Nekljudova, V., Paluch-Shimon, S., Pénault-Llorca, F., Slamon, D., Vogel, C., Von Minckwitz, G., Buyse, M., & Piccart-Gebhart, M. (2016). Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Annals of oncology, 27(6), mdw132, 1029-1034. doi:10.1093/annonc/mdw132


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/237863

Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, D., Cobleigh, M., Di Leo, A., Johnston, S. R. D. S., Gasparini, G., Kaufman, B., Marty, M., Nekljudova, V., Paluch-Shimon, S., Pénault-Llorca, F., Slamon, D., Vogel, C., Von Minckwitz, G., Buyse, M., & Piccart-Gebhart, M. (2016). Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Annals of oncology, 27(6), mdw132, 1029-1034. doi:10.1093/annonc/mdw132